Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472185 · ClinicalTrials.gov registry record · Phase 3
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 465
- Enrollment target
NCT01472185 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 465 participants.
The verdict
NCT01472185, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 465 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are treatment naive to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or thiazolidinediones \[TZDs\] for at least 24 weeks) prior to screening, and to characterize the relationship between HbA1c reduction and other glycemic parameters in subjects with T2DM.
Interventions
- DRUG Placebo
- BEHAVIORAL Exercise
- BEHAVIORAL Diet
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01472185
The ClinicalTrials.gov registry entry for NCT01472185 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01472185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01472185 about?
NCT01472185 is a clinical study titled "Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus". This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are tr...
What is the current status of trial NCT01472185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2011-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01472185?
The interventions under investigation include: Placebo (DRUG), Exercise (BEHAVIORAL), Diet (BEHAVIORAL), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01472185?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.